Literature DB >> 24743018

Detection of IL-17A-producing peripheral blood monocytes in Langerhans cell histiocytosis patients.

Magda Lourda1, Selma Olsson-Åkefeldt2, Désirée Gavhed2, Sofia Björnfot3, Niels Clausen4, Ulf Hjalmars5, Magnus Sabel6, Abdellatif Tazi7, Maurizio Aricò8, Christine Delprat9, Jan-Inge Henter2, Mattias Svensson3.   

Abstract

Langerhans cell histiocytosis (LCH) is a rare disease of unknown cause with manifestations ranging from isolated granulomatous lesions to life-threatening multi-system organ involvement. This disorder is further characterized by infiltration of immune cells in affected tissues and an association with interleukin (IL)-17A has been reported. Here, we investigated the presence of IL-17A-producing cells among peripheral blood mononuclear cells isolated from LCH patients and observed a high percentage of IL-17A(+) monocytes in peripheral blood of LCH patients compared to controls. The IL-17A(+) monocytes were also positive for the transcription factor retinoic acid orphan receptor (ROR) γt and showed increased mRNA levels for both IL-17A and RORγt. Notably, IL-17A was produced by all monocyte subsets and the expression level was positively associated with LCH disease activity. These data support a role for monocytes in the pathogenesis of LCH. Future therapeutic approaches may consider identification of patients who may benefit from IL-17A-targeted interventions.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Interleukin-17A;; Langerhans cell histiocytosis;; Monocytes;; Retinoic acid orphan receptor C; Retinoic acid orphan receptor γt;

Mesh:

Substances:

Year:  2014        PMID: 24743018     DOI: 10.1016/j.clim.2014.04.004

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  6 in total

1.  Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.

Authors:  Dmitry Evseev; Irina Kalinina; Elena Raykina; Daria Osipova; Zalina Abashidze; Anna Ignatova; Anna Mitrofanova; Alexey Maschan; Galina Novichkova; Michael Maschan
Journal:  Int J Hematol       Date:  2021-08-12       Impact factor: 2.490

2.  Acute-phase ITIH4 levels distinguish multi-system from single-system Langerhans cell histiocytosis via plasma peptidomics.

Authors:  Ichiro Murakami; Yukiko Oh; Akira Morimoto; Hitoshi Sano; Susumu Kanzaki; Michiko Matsushita; Takeshi Iwasaki; Satoshi Kuwamoto; Masako Kato; Keiko Nagata; Kazuhiko Hayashi; Shinsaku Imashuku; Jean Gogusev; Francis Jaubert; Takashi Oka; Tadashi Yoshino
Journal:  Clin Proteomics       Date:  2015-06-18       Impact factor: 3.988

3.  A T Cell View of the Bone Marrow.

Authors:  Adriana Bonomo; Ana Carolina Monteiro; Triciana Gonçalves-Silva; Eric Cordeiro-Spinetti; Rômulo Gonçalves Galvani; Alex Balduino
Journal:  Front Immunol       Date:  2016-05-17       Impact factor: 7.561

Review 4.  Merkel cell polyomavirus and Langerhans cell neoplasm.

Authors:  Ichiro Murakami; Noriko Wada; Junko Nakashima; Mitsuko Iguchi; Makoto Toi; Yumiko Hashida; Tomonori Higuchi; Masanori Daibata; Michiko Matsushita; Takeshi Iwasaki; Satoshi Kuwamoto; Yasushi Horie; Keiko Nagata; Kazuhiko Hayashi; Takashi Oka; Tadashi Yoshino; Toshihiko Imamura; Akira Morimoto; Shinsaku Imashuku; Jean Gogusev; Francis Jaubert
Journal:  Cell Commun Signal       Date:  2018-08-22       Impact factor: 5.712

5.  Altered Populations of Unconventional T Cell Lineages in Patients with Langerhans Cell Histiocytosis.

Authors:  Jenée Mitchell; Egle Kvedaraite; Tatiana von Bahr Greenwood; Jan-Inge Henter; Daniel G Pellicci; Stuart P Berzins; George Kannourakis
Journal:  Sci Rep       Date:  2018-11-07       Impact factor: 4.379

6.  Neutralizing Anti-IL-17A Antibody Demonstrates Preclinical Activity Enhanced by Vinblastine in Langerhans Cell Histiocytosis.

Authors:  Selma Olsson Åkefeldt; Mohamad Bachar Ismail; Alexandre Belot; Giulia Salvatore; Nathalie Bissay; Désirée Gavhed; Maurizio Aricò; Jan-Inge Henter; Hélène Valentin; Christine Delprat
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.